What drove the pre-market spike in TMD.TO stock?

The pre-market spike to **C$1.13** came with **117,220** shares traded, well above the **45,936** average. Thin liquidity and news around corporate restructuring and merger updates likely amplified buying pressure.

How does Meyka AI view TMD.TO stock right now?

Meyka AI rates TMD.TO with a **68.72** score, Grade **B**, and a **HOLD** suggestion. The model flags high volatility and recommends waiting for sustained volume or clear catalysts before increasing exposure.

What price targets and forecast exist for TMD.TO stock?

Meyka AI's model gives a 12-month base target of **C$0.85**, a conservative target of **C$0.60**, and a bullish target of **C$1.40**. The base target implies **-24.44%** versus the current **C$1.13**. Projections are not guarantees.

What are the main risks for TMD.TO stock investors?

Key risks include thin float, reversal risk after high-volume spikes, execution risk on product development, and transaction-related uncertainty from past merger activity. Monitor TSX liquidity and company filings closely.

CA Stocks

Pre-market TMD.TO Titan Medical (TSX) C$1.13 heavy vol Mar 2026: watch 50d

ByHuzaifa Zahoor March 2, 2026

TMD.TO stock surged to C$1.13 in pre-market trading on 02 Mar 2026, led by 117,220 shares versus an average of 45,936. This high-volume move follows thin intraday liquidity, with an open at C$0.05 and a day low of C$0.05 before the spike. Traders should note the 2.55x relative volume and the gap between the 50-day average C$0.07 and current price. We examine catalysts, valuation, and short-term technical levels ahead of the TSX open.